Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name IMC-F106C
Trade Name
Synonyms IMC F106C|IMC F106C|Brenetafusp
Drug Descriptions

IMC-F106C is a bispecific fusion protein targeting CD3 and PRAME, which potentially results in antitumor activity (Ann Oncol (2022) 33 (suppl_7): S875).

DrugClasses
CAS Registry Number NA
NCIT ID C170976

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Gemcitabine + IMC-F106C Gemcitabine IMC-F106C 0 0
IMC-F106C IMC-F106C 0 1
IMC-F106C + Nab-paclitaxel IMC-F106C Nab-paclitaxel 0 0
IMC-F106C + Nivolumab IMC-F106C Nivolumab 0 1
IMC-F106C + Pegylated liposomal doxorubicin IMC-F106C Pegylated liposomal doxorubicin 0 0
IMC-F106C + unspecified PD-1 antibody IMC-F106C unspecified PD-1 antibody 0 1
IMC-F106C + unspecified PD-L1 antibody IMC-F106C unspecified PD-L1 antibody 0 1


Additional content available in CKB BOOST